NOVARTIS AG-SPONSORED ADR
NVSNYSETrading Snapshot
- Day Range
- $142.77 – $147.06
- 52-Week Range
- $121.57 – $170.46
- Volume
- $3.41B
- Avg Volume
- $2.91B
- Shares Outstanding
- 1.90B
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $54.81B
- Last Q Revenue
- $14.42B
- P/E Ratio
- 22.2
- P/S Ratio
- 5.1x
- EPS (TTM)
- $6.64
- Dividend Yield
- 3.05%
- Dilution (1yr)
- −3.7%
Why Investors Own NVS
- ✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NOVARTIS AG-SPONSORED ADR
NVS
StockOtter · stockotter.spaceAbout NOVARTIS AG-SPONSORED ADR
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern
Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG (NYSE: NVS). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Nov
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of thei
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.